XML 143 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
EQUITY
 6 Months Ended
Jun. 30, 2013
Equity [Abstract]  
Stockholders Equity Note Disclosure [Text Block]
EQUITY


Common Stock
 
Capital in  Excess
of Par Value
of Stock
 
Retained
Earnings
 
Treasury Stock
 
Noncontrolling
Interest
Dollars and Shares in Millions
Shares
 
Par Value
 
Shares
 
Cost
 
Balance at January 1, 2012
2,205

 
$
220

 
$
3,114

 
$
33,069

 
515

 
$
(17,402
)
 
$
(89
)
Net earnings
—

 
—

 
—

 
1,746

 
—

 
—

 
859

Cash dividends declared
—

 
—

 
—

 
(1,154
)
 
—

 
—

 
—

Stock repurchase program
—

 
—

 
—

 
—

 
27

 
(875
)
 
—

Employee stock compensation plans
3

 
1

 
(331
)
 
—

 
(12
)
 
677

 
—

Distributions
—

 
—

 
—

 
—

 
—

 
—

 
(1,056
)
Balance at June 30, 2012
2,208

 
$
221

 
$
2,783

 
$
33,661

 
530

 
$
(17,600
)
 
$
(286
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at January 1, 2013
2,208

 
$
221

 
$
2,694

 
$
32,733

 
570

 
$
(18,823
)
 
$
15

Net earnings
—

 
—

 
—

 
1,145

 
—

 
—

 
21

Cash dividends declared
—

 
—

 
—

 
(1,163
)
 
—

 
—

 
—

Stock repurchase program
—

 
—

 
—

 
—

 
10

 
(364
)
 
—

Employee stock compensation plans
—

 
—

 
(719
)
 
—

 
(18
)
 
1,167

 
—

Distributions
—

 
—

 
—

 
—

 
—

 
—

 
(34
)
Balance at June 30, 2013
2,208

 
$
221

 
$
1,975

 
$
32,715

 
562

 
$
(18,020
)
 
$
2



Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method.

In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of common stock and in June 2012 increased its authorization for the repurchase of common stock by an additional $3.0 billion. Repurchases may be made either in the open market or through private transactions, including under repurchase plans established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. The stock repurchase program does not have an expiration date and may be suspended or discontinued at any time.

Noncontrolling interest in 2012 is primarily related to the partnerships with Sanofi for the territory covering the Americas for net sales of Plavix*. Net earnings attributable to noncontrolling interest are presented net of taxes of $1 million and $90 million for the three months ended June 30, 2013 and 2012, respectively, and $13 million and $319 million for the six months ended June 30, 2013 and 2012, respectively, in the consolidated statements of earnings with a corresponding increase to the provision for income taxes. Distribution of the partnership profits to Sanofi and Sanofi's funding of ongoing partnership operations occur on a routine basis. The above activity includes the pre-tax income and distributions related to these partnerships.

The components of other comprehensive income/(loss) were as follows: 
 
2013
 
2012
 
Pretax
 
Tax
 
After tax
 
Pretax
 
Tax
 
After tax
Three Months Ended June 30,
 
 
 
 
 
 
 
 
 
 
 
Derivatives qualifying as cash flow hedges :(a)
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains
$
30

 
$
(10
)
 
$
20

 
$
30

 
$
(8
)
 
$
22

Reclassified to net earnings
(34
)
 
11

 
(23
)
 
(13
)
 
4

 
(9
)
Derivatives qualifying as cash flow hedges
(4
)
 
1

 
(3
)
 
17

 
(4
)
 
13

Pension and postretirement benefits:
 
 
 
 
 
 
 
 
 
 
 
Actuarial gains
935

 
(330
)
 
605

 
—

 
—

 
—

Amortization(b)
38

 
(12
)
 
26

 
33

 
(11
)
 
22

Settlements(c)
101

 
(35
)
 
66

 
—

 
—

 
—

Pension and postretirement benefits
1,074

 
(377
)
 
697

 
33

 
(11
)
 
22

Available for sale securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains/(losses)
(54
)
 
9

 
(45
)
 
18

 
(8
)
 
10

Realized (gains)/losses
(8
)
 
3

 
(5
)
 
—

 
2

 
2

Available for sale securities(d)
(62
)
 
12

 
(50
)
 
18

 
(6
)
 
12

Foreign currency translation
(20
)
 
—

 
(20
)
 
(37
)
 
—

 
(37
)
Foreign currency translation on net investment hedges
(13
)
 
—

 
(13
)
 
41

 
—

 
41

 
$
975

 
$
(364
)
 
$
611

 
$
72

 
$
(21
)
 
$
51

 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended June 30,
 
 
 
 
 
 
 
 
 
 
 
Derivatives qualifying as cash flow hedges:(a)
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains
$
99

 
$
(33
)
 
$
66

 
$
44

 
$
(17
)
 
$
27

Reclassified to net earnings
(44
)
 
16

 
(28
)
 
(21
)
 
6

 
(15
)
Derivatives qualifying as cash flow hedges
55

 
(17
)
 
38

 
23

 
(11
)
 
12

Pension and postretirement benefits:
 
 
 
 
 
 
 
 
 
 
 
Actuarial gains
935

 
(330
)
 
605

 
19

 
(5
)
 
14

Amortization(b)
76

 
(23
)
 
53

 
69

 
(23
)
 
46

Settlements(c)
101

 
(35
)
 
66

 
—

 
—

 
—

Pension and postretirement benefits
1,112

 
(388
)
 
724

 
88

 
(28
)
 
60

Available for sale securities:
 
 
 
 
 
 
 
 
 
 
 
Unrealized gains/(losses)
(51
)
 
10

 
(41
)
 
8

 
(1
)
 
7

Realized gains
(8
)
 
3

 
(5
)
 
(10
)
 
2

 
(8
)
Available for sale securities(d)
(59
)
 
13

 
(46
)
 
(2
)
 
1

 
(1
)
Foreign currency translation
(39
)
 
—

 
(39
)
 
(22
)
 
—

 
(22
)
Foreign currency translation on net investment hedges
5

 
—

 
5

 
29

 
—

 
29

 
$
1,074

 
$
(392
)
 
$
682

 
$
116

 
$
(38
)
 
$
78


(a)
Reclassifications to net earnings of derivatives qualifying as effective hedges are recognized in cost of products sold.
(b)
Actuarial losses and prior service cost are amortized into cost of products sold, research and development, and marketing, selling and administrative expenses as appropriate.
(c)
Pension settlements are recognized in other (income)/expense.
(d)
Released (gains)/losses on available for sale securities are recognized in other (income)/expense.

The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
Dollars in Millions
June 30,
2013
 
December 31, 2012
Derivatives qualifying as cash flow hedges
$
47

 
$
9

Pension and other postretirement benefits
(2,299
)
 
(3,023
)
Available for sale securities
19

 
65

Foreign currency translation
(287
)
 
(253
)
Accumulated other comprehensive loss
$
(2,520
)
 
$
(3,202
)